- Works count
- 946
- Citation count
- 42,265
- H-index
- 88
- i10-index
- 353
Research interests
Publications
Management of Salivary Gland Malignancy: ASCO Guideline
Journal of Clinical Oncology · 2021 · https://doi.org/10.1200/jco.21.00449
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group
Radiotherapy and Oncology · 2021 · https://doi.org/10.1016/j.radonc.2021.01.013
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study
Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.04.001
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.12.007
Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.011
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32591-7
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0662-5
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Oral Oncology · 2018 · https://doi.org/10.1016/j.oraloncology.2018.04.008
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31999-8
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)31999-8
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
European Journal of Cancer · 2017 · https://doi.org/10.1016/j.ejca.2017.08.022
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30421-7
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1602252
Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study
European Journal of Cancer · 2015 · https://doi.org/10.1016/j.ejca.2015.07.043
Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial
The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)70124-5
Cabozantinib in Progressive Medullary Thyroid Cancer
Journal of Clinical Oncology · 2013 · https://doi.org/10.1200/jco.2012.48.4659
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
The Lancet Oncology · 2013 · https://doi.org/10.1016/s1470-2045(13)70181-5
Rare cancers are not so rare: The rare cancer burden in Europe
European Journal of Cancer · 2011 · https://doi.org/10.1016/j.ejca.2011.08.008
Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2010 · https://doi.org/10.1093/annonc/mdq185
Phase III Study of Gefitinib Compared With Intravenous Methotrexate for Recurrent Squamous Cell Carcinoma of the Head and Neck
Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.17.0530
Major and minor salivary gland tumors
Critical Reviews in Oncology/Hematology · 2009 · https://doi.org/10.1016/j.critrevonc.2009.10.004
Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
New England Journal of Medicine · 2008 · https://doi.org/10.1056/nejmoa075853
Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers
Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2005.05.3025
High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma
Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2005.04.6136
Primary Chemotherapy in Resectable Oral Cavity Squamous Cell Cancer: A Randomized Controlled Trial
Journal of Clinical Oncology · 2003 · https://doi.org/10.1200/jco.2003.06.146
Current projects
No projects listed.